As­traZeneca show­cas­es 83% risk re­duc­tion for long-act­ing Covid-19 an­ti­body at 6-month analy­sis

Up­dat­ed re­sults from As­traZeneca’s pre­ven­tion tri­al for its long-act­ing Covid-19 an­ti­body com­bo Evusheld sug­gest that the drug is even more ef­fec­tive at the six-month mark, sup­port­ing the case for its use to pro­tect those for whom a vac­cine may be in­suf­fi­cient.

Where­as the pri­ma­ry analy­sis on which FDA and EMA reg­u­la­tors grant­ed emer­gency use au­tho­riza­tion had a me­di­an fol­low-up of 83 days, the ex­tend­ed analy­sis traced them through six months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER